Ianalumab re-treatment for ITP or wAIHA
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a re-treatment with ianalumab for people with ITP or warm-antibody autoimmune hemolytic anemia who previously benefited from the drug in an earlier Novartis study but then had their condition return after at least 2 years. It aims to see if a second course can help again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been in a previous Novartis study for ITP or wAIHA where you received ianalumab or a placebo.
- You had a good response to treatment in that earlier study, but your condition came back at least 2 years after the last dose.
- You are not using any other treatments for ITP or wAIHA besides the study drug or allowed rescue therapies.
- You do not have other autoimmune blood disorders (like Evans syndrome) or current life-threatening bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding ianalumab to eltrombopag helps children with immune thrombocytopenia (ITP) who didn't get better with steroids. It aims to find a new option for kids whose platelet counts are low despite treatment.
This trial tests a new drug called enatumab for people with warm antibody autoimmune hemolytic anemia (wAIHA) that has come back or not improved after at least two prior treatments. The goal is to see if enatumab can help control the disease.
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
This study tests a new CAR T-cell therapy for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that hasn't improved with standard treatments. The goal is to see if this therapy can eliminate the harmful immune cells causing your condition.
This trial tests a new drug called velinotamig for adults with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that came back or didn't get better after standard treatments. The goal is to see if it can help control the immune system and improve blood counts.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.